Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ALX Oncology Holdings Inc. ALXO
$6.61
+$0.36 (5.42%)
На 18:02, 12 мая 2023
+308.47%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
263974980.00000000
-
week52high
15.39
-
week52low
4.23
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.65625000
-
EPS
-2.95000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Outperform | Outperform | 09 авг 2022 г. |
| Stifel | Buy | Buy | 06 июн 2022 г. |
| Piper Sandler | Overweight | Overweight | 19 мая 2022 г. |
| Stifel | Buy | Buy | 01 мар 2022 г. |
| Jefferies | Hold | Buy | 22 дек 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 09 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Pinto Shelly | D | 62097 | 482 | 29 дек 2022 г. |
| Randolph Sophia | D | 270253 | 1617 | 29 дек 2022 г. |
| GARCIA PETER S | D | 53723 | 893 | 29 дек 2022 г. |
| Pons Jaume | D | 539746 | 3232 | 29 дек 2022 г. |
| Randolph Sophia | D | 25340 | 25339 | 16 дек 2022 г. |
| Randolph Sophia | D | 95175 | 12731 | 16 дек 2022 г. |
| Randolph Sophia | D | 4027 | 8404 | 16 дек 2022 г. |
| Randolph Sophia | A | 271870 | 25339 | 16 дек 2022 г. |
| Randolph Sophia | A | 246531 | 12731 | 16 дек 2022 г. |
| Randolph Sophia | A | 233800 | 8404 | 16 дек 2022 г. |
Новостная лента
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 07:00
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 10:30 am PT at the Westin St. Francis in San Francisco.
ALX Oncology Announces Upcoming Investor Conference Participation
GlobeNewsWire
02 ноя 2022 г. в 07:00
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in four upcoming investor conferences.
ALX Oncology Announces Upcoming Investor Conference Participation
GlobeNewsWire
01 сент 2022 г. в 07:00
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences.